Business Context and Reporting Period
This Form 6-K filing by AC Immune SA covers the month of May 2026. The report primarily announces the publication of the invitation for the 2026 Annual General Meeting (AGM) scheduled for June 11, 2026, and details significant changes to the Company's executive leadership and Board of Directors committees.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity for the current period. Financial data for the years ended December 31, 2025, 2024, and 2023 is incorporated by reference to the Company's Annual Report on Form 20-F filed on March 13, 2026 (Exhibit 99.4), but is not restated within this document.
Material Changes
- CEO Transition: Dr. Andrea Pfeifer will retire as Chief Executive Officer after 23 years at the upcoming AGM on June 11, 2026.
- Interim CEO Appointment: Dr. Martin Zügel, currently the Chair of the Board, has been appointed Interim CEO. He will retain his role as Chair.
- Committee Resignations: Dr. Zügel resigned from the Audit & Finance Committee (AFC) and the Compensation, Nomination & Corporate Governance Committee (CNC) due to his new role as Interim CEO.
- Lead Independent Director: Dr. Monika Bütler was appointed Lead Independent Director to ensure governance oversight.
- AFC Membership: Dr. Carl June was appointed to the Audit & Finance Committee effective May 12, 2026, to maintain the required minimum of three members. The committee now consists of Dr. June, Renée Aguiar-Lucander, and Dr. Bütler.
Guidance, Outlook, and Risks
The filing does not contain financial guidance, market outlook, or specific risk factors. The primary operational focus is the ongoing search for a permanent CEO successor. The document notes that the AGM invitation and proxy cards are attached as exhibits.
Investor Verification Checklist
- Verify the full biographical details of Dr. Martin Zügel, Dr. Monika Bütler, and Dr. Carl June in the Annual Report on Form 20-F filed March 13, 2026.
- Review the Consolidated Financial Statements (Exhibit 99.4) for the most recent fiscal year performance, as this 6-K contains no new financial data.
- Confirm the timeline and criteria for the permanent CEO search process via the AGM materials (Exhibits 99.1-99.3).
- Monitor future filings for the appointment of a permanent CEO and any resulting changes to the Board committee structure.